Alzheimer’s Network for Treatment and Diagnostics. Observational study for patients who are being treated with Novel FDA approved therapies.
A Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 over 52 Weeks in Participants with Early Alzheimer’s Disease.
A Study of Remternetug Versus Placebo in Early Alzheimer’s Disease Participants at Risk for Cognitive and Functional Decline
A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY STUDY OF TRONTINEMAB IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE(MCI TO MILD DEMENTIA DUE TO AD)
MASTER SCREENING STUDY TO DETERMINE INDIVIDUALS WITH POTENTIAL TRIAL ELIGIBILITY FOR ALZHEIMER’S DISEASE STUDIES AS ASSESSED BY BIOMARKER STATUS AND COGNITION